AKT1 and prostate cancer: They subsequently demonstrated in both PC-3 and LNCaP prostate cancer cell lines that melatonin administration significantly inhibited hypoxia-mediated phosphorylation of Akt and GSK-3β, which they determined was secondary to melatonin-induced inhibition of SPHK-1.